Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of S-1 with concurrent radiotherapy after induction chemotherapy for locally advanced pancreatic cancer
ChiCTR-ONC-12003075Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Overall survival. Started Jan 2013; status: recruiting.
02
Drugs
tegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR-ONC-12003075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12003075.